Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Watson Pharmaceuticals Inc Issues FY 2012 Guidance Above Analysts' Estimates; Issues FY 2013 EPS Guidance In Line With Analysts' Estimates


Thursday, 1 Nov 2012 06:35am EDT 

Watson Pharmaceuticals Inc announced that for fiscal 2012, it expects total net revenue to be approximately $5.9 billion. Adjusted non-GAAP earnings are expected to be between $5.85 and $5.95 per diluted share (EPS). Adjusted EBITDA is expected to be between $1.36 and $1.39 billion. For fiscal 2013, it expects non-GAAP earnings per share to grow between 30% and 40% over the high-end of estimated combined range for fiscal 2012. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $5.53 billion and EPS of $5.80 for fiscal 2012; EPS of $8.21 for fiscal 2013. 

Company Quote

216.215
-1.235 -0.57%
28 Jul 2014